X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

Israel PM Says Second Booster Swells Antibodies Five Times

Content Team by Content Team
10th January 2022
in News
Israel PM Says Second Booster Swells Antibodies Five Times

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

According to Naftali Bennett, the Israeli Prime Minister, as per preliminary findings in an Israeli study, a fourth COVID-19 jab can shoot-up antibodies five times, a week after the shot is administered. At the Sheba Medical Center, Bennett said that seven days into the fourth dose, they knew for sure that it is absolutely safe. The medical center is in the process of administering second booster shots to its staff at a time when the entire country is gripped under the clutches of Omicron. It is well to be noted that Isreal has indeed played a pivotal role when it comes to studying the effects of COVID-19 vaccines. They were the fastest across the world to roll out a two-dose jab to its population almost a year back. The country was also one of the first to administer boosters, ie. the third shots.

Isreal is as of now administering the fourth dose to its citizens who are above 60 years of age and also health workers as well as immunocompromised patients. The WHO has, however, said that more people across the world should be vaccinated first before administering booster doses to others. The Sheba Trial as it is called was launched on December 27 to inoculate the fourth dose of Pfizer & BioNTech vaccine to 150 medical staff whose antibody levels had dropped to a great extent since the time they received their doses four-five months back. Another group is supposed to receive the fourth shot of the Moderna vaccine this week itself, as per Sheba

When it comes to the side effects of the vaccines, they aren’t different from the third dose like fever, pain, and headache. As per WHO data, the Omicron variant which was first detected in November last year has been spreading fast with case numbers surging at an all-time high. However, the hospitalization and the death rate is largely lower than the other phases that we have seen in the pandemic. In Israel alone, the daily rate of infections has elevated more than ten times in the past month. Although severe illness has also seen a rise, at a much slower pace, as per Health Ministry data. Israel has fully inoculated 60% of the country’s total population of 9.4 million. Some research indicates that even if Omicron dodges antibodies the key part of the second line of defense, the T-cells will be highly effective in identifying and attacking the variant.

Previous Post

Autism clinical trials now open on the TrialWire Platform

Next Post

Merck Steps Up Its Battle Against Maternal Mortality

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Next Post
Merck Steps Up Its Battle Against Maternal Mortality

Merck Steps Up Its Battle Against Maternal Mortality

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In